RX3Receiver Site 3
References in periodicals archive ?
formerly known as Rx3 Pharmaceuticals), a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections, announced today a $20 million Series A financing.
a) RA2 (a) R72 (a) R12 (a) R53 (a) R22 (a) R63 (a) R32 (a) R73 (a) R42 (a) R83 (a) R52 (a) RX3
We are excited to have these experienced biotech executives join in our efforts to build next generation antibiotics for life threatening infections," said John Finn, President of Rx3 Pharmaceuticals.
Chairman of Rx3 Pharmaceuticals as well as Chairman of its current Scientific Advisory Board.